HRP20170246T4 - Režim doziranja za selektivni agonist s1p1-receptora - Google Patents
Režim doziranja za selektivni agonist s1p1-receptora Download PDFInfo
- Publication number
- HRP20170246T4 HRP20170246T4 HRP20170246TT HRP20170246T HRP20170246T4 HR P20170246 T4 HRP20170246 T4 HR P20170246T4 HR P20170246T T HRP20170246T T HR P20170246TT HR P20170246 T HRP20170246 T HR P20170246T HR P20170246 T4 HRP20170246 T4 HR P20170246T4
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- dose
- pharmaceutically acceptable
- acceptable salt
- administered
- Prior art date
Links
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 title 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 229940125904 compound 1 Drugs 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 210000002216 heart Anatomy 0.000 claims 5
- 238000004448 titration Methods 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 238000011476 stem cell transplantation Methods 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 208000012657 Atopic disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000011221 initial treatment Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Physiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (9)
1. Spoj, naznačen time, da je (R)-5-[3-kloro-4-(2,3-dihidroksi-propoksi)-benz[Z]iliden]-2-([Z]-propilimino)-3-o-tolil-tiazolidin-4-on (Spoj 1), ili njegova farmaceutski prihvatljiva sol, koji/koja se upotrebljava u liječenju i/ili prevenciji bolesti ili poremećaja koje/koji su odabrani iz skupine koja se sastoji od:
odbacivanja transplantiranih organa, bolesti usadak protiv stanice domaćina, koja je nastala nakon transplantacije matične stanice, autoimunih sindroma izabranih od reumatoidnog artritisa, multiple skleroze, upalne bolesti crijeva odabrane od Crohnove bolesti i ulcerativnog kolitisa, psorijaze, psorijatskog artritisa, Hashimoto-tiroiditisa i uveoretinitisa, atopijske bolesti odabrane od rinitisa, konjunktivitisa i dermatitisa, astme, dijabetesa tipa I, autoimunih bolesti koje su posljedice infekcija izabranih od reumatske groznice i postinfektivnog glomerulonefritisa, solidnih vrsta raka i tumorskih metastaza,
pri čemu se Spoj 1 ili njegova farmaceutski prihvatljiva sol treba primjenjivati oralno kod ljudskog pojedinca na takav način, da se za vrijeme inicijalne faze liječenja, Spoj 1 treba davati u inicijalnoj dozi koja je između dva do pet puta ili pet do 16 puta manja nego ciljana doza, sve dok ne prestane daljnje akutno smanjenje srčane frekvencije,
gdje se akutno smanjenje srčane frekvencije odnosi na smanjenje brzine rada srca od vrijednosti srčane frekvencije prije uzimanja doze, za 10 ili više udaraca u minuti (bpm) što je maksimalna vrijednost unutar vremena od jednog do tri sata nakon uzimanja lijeka,
te nakon toga slijedi podizanje titracije s povećavanjem doze do ciljane doze,
pri čemu je ciljana doza 20 ili 40 mg Spoja 1, koja se treba davati p.o. jednom dnevno,
dok se doza koja je niža od ciljane doze, treba davati u doznim frekvencijama od jednom do dva puta dnevno, te
pritom podizanje titracije do ciljane doze, treba biti učinjeno s jednim ili s nekoliko doznih prirasta.
2. Spoj 1, ili njegova farmaceutski prihvatljiva sol za uporabu prema zahtjevu 1, naznačen/a time, da ciljana doza iznosi 20 mg Spoja 1, koja se treba davati p.o. jednom dnevno.
3. Spoj 1, ili njegova farmaceutski prihvatljiva sol za uporabu prema zahtjevu 1, naznačen/a time, da ciljana doza iznosi 40 mg Spoja 1, koja se treba davati p.o. jednom dnevno.
4. Spoj 1, ili njegova farmaceutski prihvatljiva sol za uporabu prema bilo kojem od zahtjeva 1 do 3, naznačen/a time, da se doza koja je manja od ciljane doze, treba davati pojedincu za vrijeme inicijalnih dva do četiri dana od trajanja liječenja.
5. Spoj 1, ili njegova farmaceutski prihvatljiva sol za uporabu prema zahtjevu 1 ili 2, naznačen/a time, da se Spoj 1 treba davati po 5 mg p.o. jednom dnevno za vrijeme od tri dana tijekom inicijalne faze liječenja, nakon čega slijedi podizanje titracije na 10 mg p.o. jednom dnevno u trajanju od tri dana, dok nakon toga slijedi podizanje titracije na ciljanu dozu od 20 mg koja se treba davati p.o. jednom dnevno.
6. Spoj 1, ili njegova farmaceutski prihvatljiva sol za uporabu prema zahtjevu 1 ili 2, naznačen/a time, da se Spoj 1 treba davati po 5 mg p.o. jednom dnevno u trajanju od tri dana za vrijeme inicijalne faze liječenja, nakon čega slijedi podizanje titracije na ciljanu dozu od 20 mg koja se treba davati p.o. jednom dnevno.
7. Spoj 1, ili njegova farmaceutski prihvatljiva sol za uporabu prema bilo kojem od zahtjeva 1 do 6, naznačen/a time, da su bolesti ili poremećaji koje/koji se trebaju liječiti i/ili prevenirati, odabrani iz skupine koju čine: odbacivanje transplantiranih organa izabranih od bubrega, jetre, srca i pluća; bolest usadak protiv stanice domaćina, koja se pojavila nakon transplantacije matične stanice; autoimuni sindromi izabrani od reumatoidnog artritisa, multiple skleroze, psorijaze, psorijatskog artritisa, Crohnove bolesti i Hashimotoovog tiroiditisa; te atopijski dermatitis.
8. Spoj 1, ili njegova farmaceutski prihvatljiva sol za uporabu prema bilo kojem od zahtjeva 1 do 6, naznačen/a time, da su bolesti ili poremećaji koje/koji se trebaju liječiti i/ili prevenirati, odabrane/i od multiple skleroze i psorijaze.
9. Spoj 1, ili njegova farmaceutski prihvatljiva sol za uporabu prema bilo kojem od zahtjeva 1 do 6, naznačen/a time, da se kod bolesti ili poremećaja koja/koji se treba liječiti, radi o multiploj sklerozi.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IB2008050995 | 2008-03-17 | ||
EP09721703.8A EP2278960B2 (en) | 2008-03-17 | 2009-03-12 | Dosing regimen for a selective sip1 receptor agonist |
PCT/IB2009/051030 WO2009115954A1 (en) | 2008-03-17 | 2009-03-12 | Dosing regimen for a selective s1p1 receptor agonist |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20170246T1 HRP20170246T1 (hr) | 2017-04-07 |
HRP20170246T4 true HRP20170246T4 (hr) | 2020-02-07 |
Family
ID=40786618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20170246TT HRP20170246T4 (hr) | 2008-03-17 | 2017-02-15 | Režim doziranja za selektivni agonist s1p1-receptora |
Country Status (27)
Country | Link |
---|---|
US (6) | US8785484B2 (hr) |
EP (1) | EP2278960B2 (hr) |
JP (2) | JP4846063B2 (hr) |
KR (3) | KR101718639B1 (hr) |
CN (2) | CN101980704A (hr) |
AR (1) | AR070842A1 (hr) |
AU (1) | AU2009227629B2 (hr) |
BR (1) | BRPI0909625B1 (hr) |
CA (1) | CA2716448A1 (hr) |
CY (1) | CY1118648T1 (hr) |
DK (1) | DK2278960T4 (hr) |
ES (1) | ES2617628T5 (hr) |
HR (1) | HRP20170246T4 (hr) |
HU (1) | HUE033168T2 (hr) |
IL (1) | IL208154A (hr) |
LT (1) | LT2278960T (hr) |
MA (1) | MA32233B1 (hr) |
MX (1) | MX2010009853A (hr) |
MY (1) | MY177360A (hr) |
NZ (1) | NZ588505A (hr) |
PL (1) | PL2278960T5 (hr) |
PT (1) | PT2278960T (hr) |
RU (1) | RU2519660C2 (hr) |
SI (1) | SI2278960T2 (hr) |
TW (1) | TWI434688B (hr) |
WO (1) | WO2009115954A1 (hr) |
ZA (1) | ZA201007367B (hr) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004295047B2 (en) | 2003-11-21 | 2011-03-10 | Actelion Pharmaceuticals Ltd | 5-(benz- (Z) -ylidene) -thiazolidin-4-one derivatives as immunosuppressant agents |
USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
ES2523401T3 (es) * | 2006-11-23 | 2014-11-25 | Actelion Pharmaceuticals Ltd. | Intermedios de un nuevo procedimiento para la preparación de derivados de 5-benciliden-2-alquilimino-3- feniltiazolidin-4-ona |
US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
CN101980704A (zh) * | 2008-03-17 | 2011-02-23 | 埃科特莱茵药品有限公司 | 选择性s1p1受体激动剂的给药方案 |
GB0819182D0 (en) | 2008-10-20 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Crystalline forms |
PL3409274T3 (pl) * | 2008-12-22 | 2020-06-01 | Novartis Ag | Schemat dawkowania dla agonisty receptora s1p |
EP3378854B1 (en) | 2010-01-27 | 2022-12-21 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
AU2011249789B2 (en) * | 2010-05-06 | 2015-03-19 | Novartis Ag | Dosage regimen of diaryl sulfide derivatives |
CA2895172C (en) | 2012-08-17 | 2020-08-18 | Actelion Pharmaceuticals Ltd | Process for the preparation of|(2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-|(o-tolyl)thiazolidin-4-one and intermediate used in said process |
WO2015066515A1 (en) | 2013-11-01 | 2015-05-07 | Receptos, Inc. | Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith |
MA41139A (fr) * | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
MX2020011182A (es) | 2014-12-11 | 2022-10-03 | Actelion Pharmaceuticals Ltd | Regimen de dosificacion para un agonista selectivo de receptor s1p1. |
AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
CA2973540A1 (en) | 2015-02-26 | 2016-09-01 | Novartis Ag | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker |
SI3310760T1 (sl) | 2015-06-22 | 2023-02-28 | Arena Pharmaceuticals, Inc. | Kristalinična L-argininska sol (R)-2-(7-(4-ciklopentil-3-(trifluorometil)benziloksi)-1,2,3,4- tetrahidrociklo-penta(b)indol-3-il)ocetne kisline za uporabo pri motnjah, povezanih z receptorjem S1P1 |
KR20190116416A (ko) | 2017-02-16 | 2019-10-14 | 아레나 파마슈티칼스, 인크. | 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법 |
MA47503A (fr) | 2017-02-16 | 2021-04-21 | Arena Pharm Inc | Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales |
JOP20190207A1 (ar) | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
AU2020372647A1 (en) | 2019-10-31 | 2022-06-16 | Idorsia Pharmaceuticals Ltd | Combination of a CXCR7 antagonist with an S1P1 receptor modulator |
WO2023062511A1 (en) | 2021-10-11 | 2023-04-20 | Actelion Pharmaceuticals Ltd | Methods of treating multiple sclerosis |
EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE172711T1 (de) | 1992-10-21 | 1998-11-15 | Yoshitomi Pharmaceutical | 2-amino-1, 3- propandiolverbindung und immunosuppressium |
CA2213989C (en) | 1995-12-28 | 2007-05-29 | Yoshitomi Pharmaceutical Industries Ltd. | External preparation for topical administration |
JPH11209277A (ja) * | 1998-01-19 | 1999-08-03 | Yoshitomi Pharmaceut Ind Ltd | 医薬組成物 |
US6476004B1 (en) | 1996-07-18 | 2002-11-05 | Mitsubishi Pharma Corporation | Pharmaceutical composition |
JP4153563B2 (ja) | 1997-02-27 | 2008-09-24 | ノバルティス アーゲー | 医薬組成物 |
CA2302438A1 (en) | 1997-05-19 | 1998-11-26 | Sugen, Inc. | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders |
JPH1180026A (ja) | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
AU2001278135A1 (en) * | 2000-08-03 | 2002-02-18 | Cytovia, Inc. | Method of identifying immunosuppressive agents |
WO2002080902A1 (en) | 2001-04-02 | 2002-10-17 | Astrazeneca Ab | Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp |
US20020197256A1 (en) | 2001-04-02 | 2002-12-26 | Genentech, Inc. | Combination therapy |
US6495025B2 (en) | 2001-04-20 | 2002-12-17 | Aerovironment, Inc. | Electrochemical oxygen generator and process |
DE60216458T2 (de) * | 2001-05-16 | 2007-09-27 | Nicholas P. Wilmette Plotnikoff | Verfahren zum auslösen einer anhaltenden immunreaktion |
PT1429845E (pt) | 2001-06-08 | 2009-06-15 | Novartis Ag | Tratamento ou profilaxia da rejeição de enxertos de células produtoras de insulina |
DE60235900D1 (de) | 2001-09-27 | 2010-05-20 | Kyorin Seiyaku Kk | Osuppressivum |
CN1329372C (zh) | 2001-09-27 | 2007-08-01 | 杏林制药株式会社 | 二芳基硫醚衍生物及其加成盐和免疫抑制剂 |
AU2003216054B2 (en) | 2002-01-18 | 2007-01-04 | Merck & Co., Inc. | Selective S1P1/Edg1 receptor agonists |
JP4430941B2 (ja) | 2002-01-18 | 2010-03-10 | メルク エンド カムパニー インコーポレーテッド | Edg受容体作動薬 |
GB0217152D0 (en) | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
PL375053A1 (en) | 2002-09-24 | 2005-11-14 | Novartis Ag | Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders |
EP2316431B1 (en) | 2003-04-08 | 2015-09-30 | Novartis AG | Solid oral composition comprising a S1P receptor agonist and a sugar alcohol |
MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
AU2004295047B2 (en) | 2003-11-21 | 2011-03-10 | Actelion Pharmaceuticals Ltd | 5-(benz- (Z) -ylidene) -thiazolidin-4-one derivatives as immunosuppressant agents |
WO2005123677A1 (en) | 2004-06-16 | 2005-12-29 | Actelion Pharmaceuticals Ltd | 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents |
WO2006010379A1 (en) | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as immunosuppressive agents |
JPWO2006041015A1 (ja) | 2004-10-12 | 2008-05-15 | 杏林製薬株式会社 | アミノアルコール誘導体とその付加塩及び免疫抑制剤 |
US20060090658A1 (en) * | 2004-11-01 | 2006-05-04 | Michael Phillips | Tissue marking system |
WO2006058316A1 (en) | 2004-11-29 | 2006-06-01 | Novartis Ag | Dosage regimen of an s1p receptor agonist |
MX2007011672A (es) | 2005-03-23 | 2007-11-15 | Actelion Pharmaceuticals Ltd | Nuevos derivados de tiofeno como agonistas del receptor de esfingosina-1-fosfato-1. |
JP5063581B2 (ja) | 2005-03-23 | 2012-10-31 | アクテリオン ファーマシューティカルズ リミテッド | 新規チオフェン誘導体 |
RU2412179C2 (ru) | 2005-03-23 | 2011-02-20 | Актелион Фармасьютиклз Лтд | Гидрированные производные бензо[с]тиофена в качестве иммуномодуляторов |
MX2007016505A (es) | 2005-06-24 | 2008-03-07 | Actelion Pharmaceuticals Ltd | Nuevos derivados de tiofeno. |
AR057894A1 (es) | 2005-11-23 | 2007-12-26 | Actelion Pharmaceuticals Ltd | Derivados de tiofeno |
TWI404706B (zh) | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
JP5063615B2 (ja) | 2006-01-24 | 2012-10-31 | アクテリオン ファーマシューティカルズ リミテッド | 新規ピリジン誘導体 |
US7879821B2 (en) * | 2006-01-26 | 2011-02-01 | University Of Medicine And Dentistry Of New Jersey | Method for modulating inflammatory responses by altering plasma lipid levels |
SI2069336T1 (sl) | 2006-09-07 | 2013-03-29 | Actelion Pharmaceuticals Ltd. | Derivati piridin-4-ila kot imunomodulirna sredstva |
TWI408139B (zh) | 2006-09-07 | 2013-09-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
MX2009002234A (es) | 2006-09-08 | 2009-03-16 | Actelion Pharmaceuticals Ltd | Derivados de piridin-3-il como agentes inmunomoduladores. |
RU2442780C2 (ru) | 2006-09-21 | 2012-02-20 | Актелион Фармасьютиклз Лтд | Фенильные производные и их применение в качестве иммуномодуляторов |
US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
ES2523401T3 (es) | 2006-11-23 | 2014-11-25 | Actelion Pharmaceuticals Ltd. | Intermedios de un nuevo procedimiento para la preparación de derivados de 5-benciliden-2-alquilimino-3- feniltiazolidin-4-ona |
CN101627034B (zh) | 2007-03-16 | 2013-05-15 | 埃科特莱茵药品有限公司 | 氨基-吡啶衍生物作为s1p1/edg1受体激动剂 |
JP5451614B2 (ja) | 2007-08-17 | 2014-03-26 | アクテリオン ファーマシューティカルズ リミテッド | S1p1/edg1受容体調節剤としてのピリジン誘導体 |
PT2952177T (pt) | 2007-10-12 | 2021-04-26 | Novartis Ag | Composições compreendendo moduladores do recetor de fosfato de esfingosina 1 (s1p) |
CN101980704A (zh) | 2008-03-17 | 2011-02-23 | 埃科特莱茵药品有限公司 | 选择性s1p1受体激动剂的给药方案 |
RS54970B1 (sr) * | 2008-08-27 | 2016-11-30 | Arena Pharm Inc | Supstituisani triciklični derivati kiselina kao s1p1 receptor agonisti korisni pri lečenju autoimunih i upalnih poremećaja |
GB0819182D0 (en) | 2008-10-20 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Crystalline forms |
JO3044B1 (ar) | 2008-12-22 | 2016-09-05 | Novartis Ag | نظام تناول جرعة لمنبه مستقبل s1p |
PL3409274T3 (pl) | 2008-12-22 | 2020-06-01 | Novartis Ag | Schemat dawkowania dla agonisty receptora s1p |
JP5416600B2 (ja) | 2010-01-22 | 2014-02-12 | 株式会社日立ハイテクノロジーズ | 欠陥検査装置およびその方法 |
CA2895172C (en) | 2012-08-17 | 2020-08-18 | Actelion Pharmaceuticals Ltd | Process for the preparation of|(2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-|(o-tolyl)thiazolidin-4-one and intermediate used in said process |
MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
MX2020011182A (es) | 2014-12-11 | 2022-10-03 | Actelion Pharmaceuticals Ltd | Regimen de dosificacion para un agonista selectivo de receptor s1p1. |
-
2009
- 2009-03-12 CN CN2009801101149A patent/CN101980704A/zh active Pending
- 2009-03-12 MX MX2010009853A patent/MX2010009853A/es active IP Right Grant
- 2009-03-12 EP EP09721703.8A patent/EP2278960B2/en active Active
- 2009-03-12 US US12/922,777 patent/US8785484B2/en active Active
- 2009-03-12 SI SI200931616T patent/SI2278960T2/sl unknown
- 2009-03-12 KR KR1020157002281A patent/KR101718639B1/ko active IP Right Grant
- 2009-03-12 PL PL09721703T patent/PL2278960T5/pl unknown
- 2009-03-12 PT PT97217038T patent/PT2278960T/pt unknown
- 2009-03-12 AR ARP090100886A patent/AR070842A1/es unknown
- 2009-03-12 JP JP2011500324A patent/JP4846063B2/ja active Active
- 2009-03-12 AU AU2009227629A patent/AU2009227629B2/en active Active
- 2009-03-12 CA CA2716448A patent/CA2716448A1/en not_active Abandoned
- 2009-03-12 NZ NZ588505A patent/NZ588505A/xx unknown
- 2009-03-12 WO PCT/IB2009/051030 patent/WO2009115954A1/en active Application Filing
- 2009-03-12 DK DK09721703.8T patent/DK2278960T4/da active
- 2009-03-12 LT LTEP09721703.8T patent/LT2278960T/lt unknown
- 2009-03-12 KR KR1020107022801A patent/KR20100134032A/ko active IP Right Grant
- 2009-03-12 ES ES09721703T patent/ES2617628T5/es active Active
- 2009-03-12 RU RU2010141579/15A patent/RU2519660C2/ru active
- 2009-03-12 KR KR1020147005406A patent/KR101653071B1/ko active IP Right Grant
- 2009-03-12 HU HUE09721703A patent/HUE033168T2/en unknown
- 2009-03-12 MY MYPI2010004328A patent/MY177360A/en unknown
- 2009-03-12 BR BRPI0909625-6A patent/BRPI0909625B1/pt active IP Right Grant
- 2009-03-12 CN CN201510090161.9A patent/CN104800208A/zh active Pending
- 2009-03-16 TW TW098108497A patent/TWI434688B/zh active
-
2010
- 2010-09-15 IL IL208154A patent/IL208154A/en active IP Right Grant
- 2010-10-14 ZA ZA2010/07367A patent/ZA201007367B/en unknown
- 2010-10-15 MA MA33253A patent/MA32233B1/fr unknown
-
2011
- 2011-08-30 JP JP2011186874A patent/JP4938905B2/ja active Active
-
2014
- 2014-06-18 US US14/308,598 patent/US20140303217A1/en not_active Abandoned
- 2014-07-02 US US14/322,722 patent/US10660880B2/en active Active
- 2014-07-02 US US14/322,801 patent/US20140315964A1/en not_active Abandoned
-
2015
- 2015-06-05 US US14/732,013 patent/US10251867B2/en active Active
-
2017
- 2017-02-02 CY CY20171100154T patent/CY1118648T1/el unknown
- 2017-02-15 HR HRP20170246TT patent/HRP20170246T4/hr unknown
-
2021
- 2021-09-09 US US17/470,905 patent/US20210401811A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20170246T4 (hr) | Režim doziranja za selektivni agonist s1p1-receptora | |
HRP20220359T1 (hr) | Režim doziranja ponesimoda, selektivnog agonista receptora s1p1 | |
Liu et al. | Berberine attenuates depressive-like behaviors by suppressing neuro-inflammation in stressed mice | |
US7897572B1 (en) | Theraputic methods for type I diabetes | |
NAKADA et al. | Selective cyclooxygenase-2 inhibitors reduce ureteral contraction in vitro: a better alternative for renal colic? | |
FI2981255T3 (fi) | Empagliflotsiinin terapeuttiset käytöt | |
JP2008509224A5 (hr) | ||
JP2013528650A5 (hr) | ||
RU2013145498A (ru) | Способы и композиции для лечения гиперурикемии и метаболических нарушений, связанных с гиперурикемией | |
JP2014507476A5 (hr) | ||
CA2751638C (en) | Medicinal use of 5-benzylaminosalicylic acid derivative or its salt | |
Schellack | An overview of gastropathy induced by nonsteroidal anti-inflammatory drugs: evidence-based pharmacy practice | |
JP2018505158A5 (hr) | ||
Surdyk et al. | Evaluation of the renal effects of ibuprofen and carprofen in euvolemic and volume-depleted dogs | |
Giuliano et al. | Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation | |
Zhu et al. | Indole supplementation ameliorates MCD-induced NASH in mice | |
Freston | Rationalizing cyclooxygenase (COX) inhibition for maximal efficacy and minimal adverse events | |
Beninger et al. | Subchronic MK-801 behavioural deficits in rats: partial reversal by the novel nitrate GT 1061 | |
JP2012041314A5 (hr) | ||
Ludvigsen et al. | Cardiac adaptation to hypertension in adult female Dahl salt‐sensitive rats is dependent on ovarian function, but loss of ovarian function does not predict early maladaptation | |
Yadav et al. | Pharmacological overview for therapy of gout and hyperuricemia | |
CN105837425A (zh) | (2e, 6e)-2-(3,5-二甲氧基苯基亚甲基)-6-(4-氯苯基亚甲基)环己酮及其衍生物的新应用 | |
Elibol et al. | Prenatal exposure of diclofenac sodium alters the behavioral development of young Wistar rats | |
KR101647348B1 (ko) | Shp를 유효성분으로 하는 통풍 예방 및 치료용 조성물 | |
CN104415320A (zh) | 治疗和预防痛风配方 |